Recent advances in biotechnology have led to the development of modified forms of IL-2 that aim to reduce side effects while maintaining its therapeutic benefits. These include engineered IL-2 variants and fusion proteins designed to target the cytokine more specifically to the tumor site, thereby minimizing systemic toxicity. Research is ongoing to evaluate the efficacy and safety of these new formulations in clinical trials.
